Related Experiment Video
Updated: Jun 24, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Exacerbation of psoriasis under efalizumab therapy
Efstathios Rallis1, Constantinos Verros, Evmorfia Karanikola
1Department of Dermatology, Army General Hospital, Athens, Greece. efrall@otenet.gr
Background:
Efalizumab is a recombinant humanized IgG1-kappa isotype monoclonal antibody that binds to CD11a, inhibiting T-cell activation. It has been approved for the treatment of moderate to severe plaque psoriasis. Efalizumab has been associated with the development of skin eruptions during the administration period, and this probably represents the potential psoriasis events observed during its administration.
Objective:
We report a case of exacerbation of psoriasis under efalizumab administration. A reversible increase in lymphocyte count with normal total white blood cell count was also noticed.
Conclusion:
Larger series are probably needed to establish clinical and histopathologic criteria and to determine the terminology used regarding the psoriasis adverse events seen with efalizumab treatment.
Related Concept Videos
Asthma III: Clinical Manifestations
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Clinical Manifestations
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...